vTv Therapeutics (VTVT) Debt to Equity (2014 - 2023)

vTv Therapeutics has disclosed Debt to Equity across 10 years of filings, most recently posting -$0.05 for Q1 2023.

• Debt to Equity for Q1 2023 came in at -$0.05, up 49.51% year-over-year; the trailing twelve-month figure through Mar 2023 was -$0.05 (up 49.51% YoY), and the FY2022 annual result was -$0.06, up 50.85% from the prior year.
• Debt to Equity came in at -$0.05 for Q1 2023 at vTv Therapeutics, up from -$0.06 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of -$0.02 in Q2 2019 to a low of -$0.13 in Q4 2021.
• The 5-year median for Debt to Equity is -$0.06 (2022), against an average of -$0.07.
• Across the five-year window, Debt to Equity surged 83.62% in 2019 and tumbled 261.5% in 2021, its largest moves.
• vTv Therapeutics' Debt to Equity stood at -$0.05 in 2019, then surged by 32.45% to -$0.04 in 2020, then tumbled by 261.5% to -$0.13 in 2021, then jumped by 50.85% to -$0.06 in 2022, then climbed by 24.57% to -$0.05 in 2023.
• The last three Debt to Equity figures came in at -$0.05 (Q1 2023), -$0.06 (Q4 2022), and -$0.09 (Q3 2022), per Business Quant data.